For future application of YM155 and its analogs as both stemotoxic compounds and anti-cancer drugs (Nakahara et al., 2007; Clemens et al., 2015), it is important to determine the structure of SLC35F2 to facilitate the design of more potent YM155 analogs with increased uptake, and hence enhanced stemotoxic activity. This evidence concerns the gene SLC35F2 and cancer.